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Abstract
Background—Cohort studies have demonstrated greater risk of myocardial infarction (MI)
associated with specific antiretroviral use, while meta-analyses of randomized controlled trials
have not. These differences may be due to inherent biases in the observational study design or to
the limited duration of randomized trials. We conducted a new-user, active-comparator cohort
study emulating a randomized controlled trial comparing initiation of several antiretrovirals as part
of combination antiretroviral therapy (cART) and MI.
Methods—We included North Carolina (NC) Medicaid beneficiaries infected with HIV between
2002 and 2008 who were previously untreated with cART. We compared hazard ratios (HRs) and
95% confidence intervals (CIs) of MI between abacavir and tenofovir recipients, and lopinavir-
ritonavir or atazanavir recipients and non-nucleoside-reverse-transcriptase-inhibitor (NNRTI)
recipients. We adjusted for confounding through inverse-probability-weighting methods.
Results—There were 3,481 NC Medicaid new cART recipients who contributed 6,399 person-
years and experienced 38 MI events. Receiving abacavir compared with tenofovir as part of cART
was associated with an increased rate of MI unadjusted (HR= 2.70 [95% CI= 1.24 - 5.91]; HR=
2.05 [0.72 - 5.86]). Point estimates also suggest a relationship between receipt of atazanavir or
lopinavir-ritonavir compared with an NNRTI and MI, although, estimates were imprecise.
Corresponding author: Emily Suzanne Brouwer, Department of Pharmacy Practice and Science, Institute for Pharmaceutical
Outcomes and Policy, University of Kentucky, 789 South Limestone, Room 243, Lexington, KY 40536-0596,
emily.brouwer@uky.edu.
SDC Supplemental digital content is available through direct URL citations in the HTML and PDF versions of this article
(www.epidem.com). This content is not peer-reviewed or copy-edited; it is the sole responsibility of the author.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Epidemiology. Author manuscript; available in PMC 2015 May 01.
Published in final edited form as:






















Conclusions—We found an increased rate of MI among patients initiating abacavir compared
with tenofovir although the association was decreased after confounding adjustment. Without a
very large prospective comparative clinical trial, a much larger observational study of patients
initiating cART would be needed to better define this apparent association.
The burden of disease among patients with Human Immunodeficiency Virus (HIV) infection
has changed since the development of potent combination antiretroviral therapy (cART).
With these important new therapies, conditions not related to-Acquired Immune Deficiency
Syndrome (AIDS) are replacing AIDS-defining conditions as major causes of morbidity and
mortality in HIV-infected patients.1 In this context, comparative effects of specific
antiretroviral medications on cardiovascular disease, specifically myocardial infarction (MI)
have been intensively evaluated. Results from two large cohort studies (Data Collection on
Adverse Events of Anti-HIV Drugs and the Strategies for Management of Antiretroviral
Therapy) suggest an increased risk of MI with current or recent, but not cumulative, use of
abacavir.2,3 More recent observational studies have also shown an increased risk of MI
associated with abacavir, 4-7 while others have not. 7,8 In contrast, meta-analyses of
randomized controlled trials (RCTs) have not shown the same increased risk.9-11
Furthermore, cohort studies have demonstrated an association between cumulative exposure
to first-generation protease inhibitors and MI-likely related to effects these medications have
on lipid profiles.12,13
Some of the observed increased risk for MI among patients exposed to abacavir in
observational studies may be attributed to confounding; patients prescribed abacavir were at
a higher baseline risk for co-morbid conditions that increase the risk of cardiovascular
disease.7 Many of the studies demonstrating an increased risk include prevalent users of
antiretroviral medications. Inclusion of prevalent users makes it difficult to distinguish true
confounders from clinical conditions affected by prior treatment and the under-
ascertainment of events, particularly if the events occur early in treatment. 14 Furthermore,
these observational studies used different comparison groups rendering it difficult to
compare the results. While RCTs may not be subject to the same biases as observational
studies, the shorter cumulative follow-up times and younger, healthier, populations may a
reduce power to detect a difference between treatment groups.
To address the discrepancy between observational studies and meta-analyses of RCTs, it is
important to design an observational study that would mimic a RCT.15 The use of a first-
treatment-carried-forward (intention-to-treat in an RCT), new-user, active-comparator
design attempts to define study cohorts with treatment equipoise, thus reducing the potential
for confounding and selection bias. We used this type of cohort study design to examine the
effects of initiating specific antiretroviral therapies on the risk for MI among previously
untreated HIV-infected patients receiving combination antiretroviral therapy. Our study
included three comparison groups (study arms): (1) tenofovir compared with abacavir (2)
atazanavir compared with NNRTIs and (3) lopinavir compared with NNRTIs (Figures 1A
and 1B).
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Data source and Study Population
We implemented this cohort study using North Carolina (NC) Medicaid administrative data
obtained for the years 2002-2008. The Medicaid program is state-and federally funded to
provide health care benefits to persons with low income. The data contain health-care-
service-reimbursement information, including that which is recorded for beneficiaries who
are also eligible for Medicare.16
To be eligible for this study, patients had to (1) be ≥ 18 years of age (2) be HIV-infected,
based on administrative criteria (ICD-9 code 042.xx or a claim for one of the 26 FDA-
approved antiretroviral medications), (3) have at least 180 days of Medicaid eligibility prior
to study entry, and (4) be new recipients of a cART regimen. A regimen was defined as a
group of antiretrovirals dispensed on the same day. A cART regimen contains (1) two
nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) as a backbone, and (2) an
anchor antiretroviral that is either an NNRTI, a protein inhibitor [PI], boosted or un-boosted
with ritonavir (an integrase strand transfer inhibitor [ISTI] or an additional NRTI. For this
study, we considered only cART regimens containing lamivudine or emtricitabine as one of
the two NRTIs in the backbone, given that all preferred initial treatment regimens include
one of these agents.17 The second NRTI was either abacavir or tenofovir. A new cART
regimen recipient was defined as a patient receiving a cART regimen with all medications
started on the same day, without a prescription filled for any antiretroviral in the 180 days
prior to study entry, with the exception of < 30 days of a non-cART regimen (e.g.
monotherapy or dual therapy). We excluded new recipients with a regimen dispensed for <
30 days followed by a non-standard cART regimen and patients with any claims for MI
(acute or chronic), coronary artery bypass graft or percutaneous transluminal coronary
angioplasty in the 180 days prior to cART initiation. For all analyses, we excluded patients
on regimens that contained both the exposed (treated) and active comparator antiretroviral
(e.g. abacavir and tenofovir).
Exposure and Outcome Definitions
Our primary outcome was myocardial infarction, defined in the Medicaid data by a
diagnosis code of 410.xx in any position and a length of stay ≥ 1 day. This algorithm was
previously validated in the NC Medicaid population (sensitivity=0.765 [95% confidence
interval (CI)=0.501 - 0.932]; specificity=0.989 [0.980 - 0.994]).18 We first considered
patients who had not previously received the most common NRTIs, abacavir and tenofovir.
Next we considered patients who had not previously received atazanavir (boosted and
unboosted with ritonavir) or lopinavir-ritonavir separately from NNRTIs.
Confounder and Covariates
We identified potential confounders of the antiretroviral use-MI relationship based on expert
knowledge about the relationship of these factors with the exposure and the outcome. We
obtained data on potential confounders from the Medicaid data in the 180 days prior to
cART initiation. We included age at study entry, sex, race, calendar year of antiretroviral
initiation (6 indicator variables for calendar year), concomitant cardiovascular medication
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use (angiotensin converting enzyme [ACE] receptor inhibitors, angiotensin receptor
blocking agents, beta receptor blocking agents, calcium channel receptor blocking agents
and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors), comorbidities in the 180 days
prior to cART initiation (based on ICD-9 codes from the Deyo implementation of the
Charlson comorbidity score,19 used separately, i.e., not as a score), number of
hospitalizations in the 180 days prior to cART initiation (0, 1-2, >2 hospitalizations) and
number of medication claims in the 180 days prior to cART initiation (0, 1-15, 15-20, >20
medications). For the NRTI comparative analysis, we considered regimen type based on
anchor antiretroviral (ritonavir boosted PI- or ISTI -based, NNRTI-based, ritonavir
unboosted PI-based, triple NRTI-based).
Statistical Analysis
To account for baseline differences in treatment, we utilized a form of inverse-probability-
weighting methodology. Inverse probability weighting relies on the propensity score,
calculated as the conditional probability of receiving active treatment. As we were interested
in estimating the average treatment effect in three active treatment populations, we weighted
the data to create a pseudo-population of patients with the same distribution of patient
characteristics as patients initiating tenofovir for the NRTI comparison and the same as
patients initiating atazanavir or lopinavir-ritonavir for the NNRTI/PI comparisons. Patients
receiving tenofovir, atazanavir or lopinavir-ritonavir received a weight of 1 and patients
receiving abacavir or an NNRTI received a weight defined as ê/(X)/(1 − ê(X)) where ê(X) is
the propensity score.20,21 Before creating the weighted pseudo-populations, we trimmed
non-overlapping regions of the propensity score distributions to exclude patients with
characteristics that had a zero probability of initiating one of the drugs compared (non-
positivity).
Follow-up started on the day of the collection of claims for the new cART regimen and
continued until the occurrence of (1) MI, 2) discontinuation of Medicaid eligibility or, 3)
end of study period (31 December 2008), whichever came first. We calculated overall
unadjusted incidence rates for MI using Poisson regression. We then used inverse
probability weights to create adjusted Kaplan-Meier curves for each of the study comparison
groups. Finally, we created Cox-proportional-hazard regression models to examine
unadjusted and inverse probability weighted hazard ratios (HR) and corresponding 95% CIs
to evaluate the effect of each active treatment in the treated populations. For weighted
analyses we used robust variance estimation. Point estimates and associated 95% CIs for
risk differences were derived from 500 bootstraps of weighted data. This study was
approved by the University of North Carolina IRB. Analyses were conducted using SAS,
Version 9.2 Copyright, SAS institute Inc. or Stata Statistical Software Release 11, College
Station, Tx, StataCorp LP. SAS and all other SAS institute Inc product or service names are
registered trademarks of SAS institute Inc, Cary, NC USA.
Sensitivity Analyses
We conducted sensitivity analyses to address treatment switch or discontinuation and
unmeasured confounding. We censored patients (1) at the first MI, (2) stopping or switching
antiretrovirals, or (3) subject to administrative censoring. We also evaluated Kaplan-Meier
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curves for time-to-treatment switch or discontinuation, stratified by treatment. We used
established methodology to assess the role of unmeasured confounding on our results.22
Results
Study Population and Descriptive Statistics
Between 1 January 2002 and 31 December 2008, 13,006 HIV-positive beneficiaries enrolled
in NC Medicaid. Of these, 3,500 beneficiaries were new recipients of a qualifying cART
regimen (Figure 2). Overall, the distribution of patient characteristics receiving an initial
cART regimen was similar to those of the overall HIV patient population; however, the
Medicaid population represents a larger proportion of HIV-infected women. Of the 10,082
patients prescribed antiretrovirals, 18% received regimens containing two NRTIs and an
NNRTI. This also was the predominant regimen type among initial cART recipients (33%).
The distribution of patient characteristics among new recipients of cART was generally
similar among recipients of specific antiretrovirals. We noted differences in comorbidities,
regimen type and year of antiretroviral initiation among recipients of abacavir or tenofovir
(Table 1). Based on ICD-9 codes, a greater proportion of abacavir recipients had renal
disease at baseline (5% vs. 2%). Conversely, a larger proportion of tenofovir recipients had
mild liver disease (4% vs.2%) and a diagnosis of cancer (5% vs. 4%). Most abacavir
recipients initiated cART before 2006 (60%) while the majority of tenofovir recipients
initiated cART during or after 2006 (64%) (Table 1). Baseline characteristics of patients
receiving atazanavir, lopinavir, or NNRTIs were generally similar (Table 2).
Comparative Safety Results
Overall, patients contributed 6,399 person-years and experienced 38 MI events. The
unadjusted incidence rate of MI for the entire new cART population was 5.9 (95% CI= 4.3 -
8.2) per 1000 person-years of follow-up. Unadjusted incidence rates for each of the study
groups are displayed in Table 3. Patients initiating abacavir or tenofovir had an unadjusted
incidence rate of 11.9 (95% CI= 7.2 - 19.7) and 4.5 (2.5 - 8.2) per 1000 person-years of
follow-up (Table 3).
Unadjusted Cox proportional hazard regression models showed an increased HR of MI
among recipients of abacavir compared with tenofovir (HR= 2.70 [95% CI= 1.24 - 5.91]). If
all those who actually initiated tenofovir had initiated abacavir instead, these patients would
have been twice as likely to have an MI. However, the HR point estimate was closer to the
null and less precise when compared with the crude (HR= 2.05 [0.72, 5.86]). Figures 3 and 4
display Kaplan-Meier curves for the inverse probability weighted pseudo-populations for
each of the study groups stratified by active or comparator antiretroviral. The absolute
difference in MI risk at 5 years after cART initiation for those receiving abacavir compared
with tenofovir was 3.5 per 100 (95% CI= -1.6 to 8.6). Unadjusted and inverse probability
weighted models did not demonstrate clinically meaningful differences in HRs of MI among
the other comparison groups (Table 3).
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To address treatment switch or discontinuation, we attempted an analysis similar to a per-
protocol analysis in an RCT; however, we did not have an adequate number of events to
address this question. Among patients receiving cART regimens containing abacavir, the
median time to regimen switch or discontinuation was 34 days compared with 58 days
among patients receiving cART containing tenofovir (log-rank p-value=0.01). Patients
initiating cART containing an NNRTI remained on their initial cART regimen longer than
those initiating cART containing atazanavir or lopinavir-ritonavir (p-value all < 0.01)
(Figures 5A, 5B, 5C). A sensitivity analysis evaluating the potential impact of unmeasured
confounding demonstrated that the magnitude of an association between an unmeasured
confounder and initiation of specific cART, as well as the association between the same
unmeasured confounder and MI, would need to be very large to reduce the observed HR
from 2.05 to 1.0 (eFigure 1).
Discussion
We simulated three active comparison RCTs by including patients who were initiating
specific antiretroviral medications as a part of guideline-recommended cART. This study
design allowed us to evaluate the effects of initial treatment with specific antiretroviral
medications on the risk for MI. We found that patients treated initially with abacavir as part
of a new cART regimen – but not atazanavir or lopinavir – had an increased rate of MI when
compared with patients treated initially with tenofovir or an NNRTI.
There are proposed biological mechanisms for an increased rate of MI among patients
exposed to abacavir, although the exact underlying pathophysiology remains unclear. HIV
infection influences factors related to inflammation and endothelial function, 23-26 and
initiation of antiretroviral therapy generally improves these factors. 26-28 Conversely,
treatment with abacavir may impair endothelial function and increase inflammation.
However, results are conflicting.29-31 More recent evidence suggests that abacavir increases
platelet reactivity, thus increasing MI risk. 32,33
The risk of MI over the five-year period observed in our data was 3%. Kowalska and
colleagues34 calculated five-year predicted MI risks for varying risk categories using the
Data Collected on Adverse Events of Anti-HIV Drugs study. Patients who smoked and had
high lipid levels had a predicted risk of MI at 5 years, similar to that observed in our study.
There are more men in the Kowalska et al study than in the HIV-infected Medicaid
population, however. The age-and sex-standardized five-year MI risk for persons who
smoke and have a high cholesterol ratio in the Framingham study is lower (0.8%) than we
observed.35 We would expect a higher risk of MI in our population than in the general
population. It is plausible that the risk to patients enrolled in the Adverse Events study is
similar to that in our own study, given that our Medicaid cohort, which (despite having a
higher proportion of women), would reflect the increased risk that comes with low
socioeconomic status. 36
The observed HRs point estimates comparing the use of abacavir to tenofovir are consistent
with (although slightly higher than) results from other observational studies on abacavir and
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MI.2,4-6 Our results do not concur with results from clinical trials. The 95% CI for the HR in
our study overlaps the null and we thus cannot exclude chance as an alternative explanation.
Nonetheless, the magnitude of the adjusted HR speaks against residual and unmeasured
confounding as alternative explanations. We did observe that trimming the upper tails of the
propensity score distribution for abacavir vs tenofovir treatment attenuated the HR, which
may suggest that treatment heterogeneity may be present, with the potential to influence our
results.
In general, RCTs aim to establish efficacy whereas observational studies evaluate
effectiveness and safety; the mere enrollment and follow-up in a RCT may result in different
outcomes than would occur among patients followed in a general clinical setting. Patients
enrolled in RCTs are often healthier and have a lower risk of comorbidities.37,38 Disparate
conclusions from meta-analyses and observational studies may be due to differing lengths of
follow-up and overall characteristics of the study population. The average length of follow-
up in the RCTs was much longer than in our study (591 days vs. 38 days).11However, the
total person-time of follow-up in our study was greater; patients included in the abacavir-
tenofovir analysis contributed a combined 3,697 person-years of follow-up compared with
an average 719 person-years among the collective RCTs in the FDA-sponsored meta-
analysis. 11This meta-analysis did not consider length of follow-up when calculating the
summarized risk difference, making the interpretation of those results more difficult.
Some observational studies evaluating the risk of MI among patients prescribed abacavir
demonstrated evidence of confounding and effect modification.6 Using a large cohort of
military veterans, Bedimo et al.8 showed that the observed relationship between abacavir use
and MI may be due to differential prescribing. Patients with baseline comorbidities that
increase the risk of MI, such as chronic kidney disease, were more likely to receive abacavir.
However, an observational study conducted using the same veterans database found an
association between abacavir and MI, with less evidence of confounding due to baseline
kidney dysfunction. 7 We also noted baseline differences in comorbidities between
antiretroviral exposure groups. We addressed these known baseline clinical differences
through inverse probability weighting and showed that this approach successfully balanced
differences in cardiovascular risk factors within each of the treatment groups.
One main concern regarding the use of administrative data is the inability to obtain
information on potentially important confounding variables (such as CD4 count, HIV RNA,
LDL cholesterol and history of smoking) that may be related to treatment assignment and
MI. Therefore, it is possible that our findings could be subject to unmeasured confounding.
Our study design limits the potential for unmeasured confounding by both indication (likely
similar for the treatment regimens compared) and frailty.39-41 Using the available variables
in the data to create inverse probability weights, we anticipate that these unmeasured factors
are likely balanced. However, we cannot confirm this. Research on frailty has shown that
older or terminally ill patients with substantial comorbidity may be under-treated due to the
expectation of shortened life expectancy.41,42
We considered only specific cART regimens that contained lamivudine or emtricitabine,
which may have reduced our sample size. Further, follow-up time was relatively short,
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resulting in reduced numbers of MI events and low precision of estimates. A limited sample
of patients initiating atazanavir and lopinavir constrained our ability to detect a difference
between these groups. Finally, due to inadequate sample size, we were unable to conduct an
analysis of treatment stop and discontinuation. This type of analysis would allow us to avoid
bias from treatment changes during follow-up but at the price of introducing the potential for
selection bias – which we avoid in our analysis of first treatment carried forward. With
adequate sample size, both a first-treatment-carried-forward analysis and an analysis of
treatment-stop and discontinuation would give us the ability to assess the impact of selection
and attrition bias on our results.
Another concern with administrative data is the potential for medication exposure
misclassification. Recently, Medicaid agencies in New York, Florida, and Pennsylvania
reported that some patients sold antiretrovirals and other chronic-disease medications
received through Medicaid on the black market. 43 If this had occurred in NC during our
study period, we would expect the misclassification to be non-differential. However, to our
knowledge, this activity was not prevalent in this state. It should also be noted that, while
those included in this study had not received antiretrovirals in the previous six months via
Medicaid (which we used this as a surrogate for antiretroviral naïve status), some patients
may have had unobserved previous antiretroviral exposures. We do not believe that the
inclusion of non-naïve patients would have a substantial impact on our results. Nonetheless,
the concern warrants further investigation, either by expanding the period of required
Medicaid eligibility prior to antiretroviral initiation or by linking the administrative data to a
more comprehensive clinical record. Further, we were unable to determine reasons for lack
of eligibility and therefore unable to discern losses to follow-up and death, as both of these
instances would result in loss of Medicaid eligibility.
The new-user design is often used for comparative safety and effectiveness research, as it
allows for the ascertainment of events that may have occurred early after treatment
initiation, and limits the potential for confounding. 14,39 Preferential prescribing of one
cART regimen or another regimen based on comorbidities (as described above) is unlikely
to be as important when considering patients receiving second or third line treatments,
which are often included in a prevalent-user study. However, the choice of initial cART is
likely linked to future treatment decisions, rendering the new-user design relevant when
assessing antiretroviral treatment outcomes. Finally, this study design allows for the
assessment of confounders at the time of antiretroviral initiation, thus reducing the influence
of time-dependent confounders on the causal pathway.15
We used an active-comparator, new-user design in combination with a first-treatment-
carried-forward analysis and a validated algorithm for identifying myocardial infarction. To
our knowledge, this type of study design has not previously been used to examine the
relationship between antiretroviral use and MI. Studies completed to date have defined
exposure to specific antiretrovirals as “any/recent/cumulative” use and compared these
definitions to no use of the antiretroviral in question.2,4-6,8 While important, these types of
comparisons make it difficult to compare across studies, particularly studies relating to HIV,
as “no-use” is likely to equate to use of some other antiretroviral that differs by study. This
heterogeneity of comparison group makes generalization across populations difficult, as
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treatment patterns may differ. While the Data Collection on Adverse Events of Anti-HIV
Drugs study 2 and other clinical cohort collaborations have superior sample size and follow-
up, our study design is unique and our results are potentially more generalizable to patients
receiving regular clinical care in the United States. Additionally, almost half of our study
population were women, whereas other observational studies have included between 2% and
27% women.2-5, 8, 10-12 This further improves the generalizability of our results.
Despite the limitations of our study and those inherent in all observational studies, such as
unmeasured confounding, our results demonstrate an increased risk for MI among patients
initiating abacavir compared with tenofovir as part of a standard cART regimen. To confirm
these findings, future studies should use active-comparison designs, and include more HIV-
infected patients initiating cART as well as information on important confounding factors
not available in administrative data.
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Appendix
We conducted a sensitivity analysis to examine the impact of a potential unmeasured clinical
factor on our observed results using the methodology proposed by Schneeweiss.22 Figure 1
displays the magnitude of the association between a potential unmeasured clinical
confounder and exposure (cART regimen) (OREC) as well as the association between the
same unmeasured confounder and outcome (MI) (ORCD) needed nullify the observed
relationship. The prevalence of the unmeasured clinical factor was set at 50% and the
prevalence of exposure was set at 25%.
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Strength of an unmeasured clinical factor needed to eliminate observed relationship between
initiation of cART containing abacavir vs. cART containing tenofovir.
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Active-comparator, new-user study design. HIV-positive patients who were initiators of
combination antiretroviral therapy (cART) in the North Carolina Medicaid program between
2002 and 2008.
A.) Comparisons of the nucleoside reverse transcriptase inhibitors abacavir and tenofovir
with any anchor antiretroviral plus lamivudine/emtricitabine (standard of care; Group 1).
B.) Comparisons of specific anchor antiretrovirals (the protease inhibitors atazanavir [Group
1] or lopinavir-ritonavir [Group 2] vs. any non-nucleoside reverse transcriptase inhibitor)
plus lamivudine/emtricitabine and any nucleoside reverse transcriptase inhibitor.
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Assembly of the combination antiretroviral therapy initiator cohort.
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Inverse probability weighted Kaplan-Meier curves for the time to a myocardial infarction
event among HIV-positive persons (identified by ICD-9 code and antiretroviral use in
administrative claim) initiating nucleoside reverse transcriptase inhibitors as part of a new
combination antiretroviral therapy (cART) regimen. Abacavir compared with tenofovir.
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Figures 4a and b.
Inverse probability weighted Kaplan-Meier curves for the time to myocardial infarction
event among HIV-positive persons (identified by ICD-9 code and antiretroviral use in
administrative claim) initiating protease inhibitors or non-nucleoside reverse transcriptase
inhibitors (NNRTI) A. atazanavir alone or in combination with ritonavir compared with non-
nucleoside reverse transcriptase inhibitors (efavirenz or nevirapine) B. lopinavir-ritonavir
compared with non-nucleoside reverse transcriptase inhibitors (efavirenz or nevirapine).
Note: axes focused on 90% to 100% surviving.
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Figures 5a, 5b, and 5c.
Kaplan-Meier curves for the time to treatment switch or discontinuation among HIV-
positive persons (identified by ICD-9 code and antiretroviral use in administrative claim)
initiating combination antiretroviral therapy. A. Abacavir compared with tenofovir B.
atazanavir alone or in combination with ritonavir compared with non-nucleoside reverse
transcriptase inhibitors (efavirenz or nevirapine) C. lopinavir-ritonavir compared with non-
nucleoside reverse transcriptase inhibitors (efavirenz or nevirapine).
Note: different time scale for part B. compared with parts A. and C.
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Table 1
Baseline characteristics of HIV-infected North Carolina Medicaid patients initiating
abacavir or tenofovir as a part of a new combination antiretroviral therapy (cART)
regimen before and after inverse probability weighting














 Female 300 (49) 758 (47) 777 (49) 744 (48)
Age (years)
 <40 247 (40) 364 (60) 684 (43) 674 (43)
 40-50 373 (61) 238 (39) 630 (40) 602 (39)
 >50 485 (27) 126 (21) 269 (17) 281 (18)
Race
 Black 450 (74) 1221 (75) 1195 (76) 1182 (76)
 White 113 (18) 287 (18) 296 (19) 280 (18)
 Asian NAb NAb NAb NAb
 Native American/Pacific Islander NAb 24 (2) 26 (2) 22 (1)
 Unknown 41 (7) 68 (4) 63 (4) 68 (4)
Comorbidity at baselinec
 Heart Failure 32 (5) 66 (5) 64 (4) 74 (5)
 Peripheral Vascular Disease NAb 14 (1) 12 (1) NAb
 Cerebrovascular Disease 23 (4) 45 (3) 41 (3) 45 (3)
 Mild Liver Disease 13 (2) 65 (4) 52 (3) 52 (3)
 Renal Disease 29 (5) 25 (2) 25 (0.4) 25(2)
 Diabetes (uncomplicated) 39 (6) 96 (6) 99 (6) 94 (6)
 Cancer 24 (4) 83 (5) 80 (5) 77 (5)
 Chronic Pulmonary Disease 44 (7) 121 (8) 115 (7) 117 (8)
Prior Medications Used (180 days before entering study)d
 HMG-CoA Reductase Inhibitors 53 (9) 113 (7) 116 (7) 101 (6)
 Calcium Channel Blockers NAb 31 (2) 31 (2) 31 (2)
 Beta Blocking agents 14 (2) 55 (3) 61 (4) 43 (3)
 Angiotensin Converting Enzyme Inhibitors (ACE-I) 40 (7) 97 (6) 102 (6) 85 (5)
No. Prior Medications Used (180 days before entering study)
 0 96 (16) 156 (10) 161 (10) 155 (10)
 1-15 412 (67) 1,126 (70) 1081 (68) 1101 (71)
 15-20 49 (8) 183 (11) 191 (12) 162 (10)
 >20 54 (9) 140 (9) 150 (9) 139 (9)
No. Hospitalizations (180 days before entering study)
 0 377 (62) 989 (62) 963 (61) 975 (63)
 0-2 121 (20) 316 (20) 302 (19) 312 (20)
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 >2 113 (18) 300 (19) 317 (20) 270 (17)
First Antiretroviral Regimene
 2 NRTIs+boosted PI/ISTI 165 (27) 644 (40) 684 (43) 639 (41)
 2 NRTIs+NNRTI 139 (23) 805 (50) 739 (47) 762 (49)
 2 NRTIs+ unboosted PI 111 (18) 165 (27) 132 (8) 129 (8)
 Triple NRTI 196 (32) 27 (2) 27 (1.7) 27 (2)
Year of Antiretroviral Initiation
 2002 39 (6) 31 (2) 27 (1.7) 31 (2)
 2003 100 (16) 101 (6) 99 (6) 101 (6)
 2004 79 (13) 146 (9) 155 (10) 146 (9)
 2005 150 (25) 305 (19) 329 (21) 305 (20)
 2006 107 (18) 346 (22) 361 (23) 342 (22)
 2007 37 (6) 132 (8) 137 (9) 130 (8)
 2008 99 (16) 2008 (34) 474 (9) 502 (32)
a
Propensity score based on the following characteristics: age, race, sex, comorbidities, drug use in the 180 days prior to antiretroviral initiation,
cardiovascular drug use in the 180 days prior to antiretroviral initiation, hospitalization in the 180 days prior to antiretroviral initiation, regimen
type, year of initiation (6 indicator variables for year). The median propensity scores for the receipt of abacavir or tenofovir were 0.60 (IQR: 0.15,
0.82; Full Range: 0.02, 0.92) and 0.84 (IQR: 0.78, 0.88; Full Range: 0.15, 0.97) respectively. 49 patients who had characteristics that were always
associated with abacavir (n=1) or tenofovir (n=48) initiation were excluded from weighted analysis. After trimming of non-overlap in the
propensity score distributions, IP weights used to estimate the effect of initiation of cART regimens containing abacavir compared with tenofovir
ranged from 0.02 to 12.0.
b
Numbers in cell < 11 (cannot be presented based on data use agreement with North Carolina Medicaid). Cells < 11 presented for pseudo-
population as persons could be represented more than once.
c
Comorbidities include: Heart failure, peripheral vascular disease, cerebrovascular disease, mild liver disease, moderate/severe liver disease, renal
disease, diabetes (uncomplicated), diabetes (complicated), cancer, metastatic carcinoma, connective tissue disease, chronic pulmonary disease,
dementia. Comorbidities with > 11 subjects in at least one cell of the baseline population presented.
d
Angiotensin receptor blocking agent percentages not presented as there was at least one cell in the baseline population that had < 11 subjects.
NA indicates not available; NRTI, Nucleoside Reverse Transcriptase Inhibitor; NNRTI, Non-Nucleoside Reverse Transcriptase Inhibitor; PI,
Protease Inhibitor. HMG-CoA, 3-hydroxy-3-methyl-glutaryl-CoA
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